Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
18. November 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
15. November 2024 16:05 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
14. November 2024 08:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Announces Proposed Public Offering
13. November 2024 16:33 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
12. November 2024 17:29 ET
|
Calidi Biotherapeutics, Inc
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s systemic...
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
24. Oktober 2024 08:30 ET
|
Calidi Biotherapeutics, Inc
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases,...
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23. Oktober 2024 08:31 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
30. September 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
13. August 2024 17:37 ET
|
Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
29. Juli 2024 09:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...